MA42361A1 - Composition pharmaceutique contenant, en tant que principe actif, un dérivé ou un sel pharmaceutiquement acceptable de 7-azaindolin-2-one - Google Patents

Composition pharmaceutique contenant, en tant que principe actif, un dérivé ou un sel pharmaceutiquement acceptable de 7-azaindolin-2-one

Info

Publication number
MA42361A1
MA42361A1 MA42361A MA42361A MA42361A1 MA 42361 A1 MA42361 A1 MA 42361A1 MA 42361 A MA42361 A MA 42361A MA 42361 A MA42361 A MA 42361A MA 42361 A1 MA42361 A1 MA 42361A1
Authority
MA
Morocco
Prior art keywords
azaindolin
pharmaceutically acceptable
salt
pharmaceutical composition
active ingredient
Prior art date
Application number
MA42361A
Other languages
English (en)
Inventor
Byeong-Seon Jeong
Jung-Ae Kim
Tae-Gyu Nam
Original Assignee
Lg Chemical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Chemical Ltd filed Critical Lg Chemical Ltd
Publication of MA42361A1 publication Critical patent/MA42361A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention concerne un dérivé ou un sel pharmaceutiquement acceptable de 7 azaindolin-2-one. Ledit dérivé ou sel pharmaceutiquement acceptable de 7-azaindolin-2-one peut être utilisé avantageusement comme substance médicinale pour inhiber la croissance du cancer et de métastases cancéreuses.
MA42361A 2015-11-12 2016-10-31 Composition pharmaceutique contenant, en tant que principe actif, un dérivé ou un sel pharmaceutiquement acceptable de 7-azaindolin-2-one MA42361A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20150158695 2015-11-12
PCT/KR2016/012409 WO2017082569A1 (fr) 2015-11-12 2016-10-31 Composition pharmaceutique contenant, en tant que principe actif, un dérivé ou un sel pharmaceutiquement acceptable de 7-azaindolin-2-one

Publications (1)

Publication Number Publication Date
MA42361A1 true MA42361A1 (fr) 2018-09-28

Family

ID=58695675

Family Applications (1)

Application Number Title Priority Date Filing Date
MA42361A MA42361A1 (fr) 2015-11-12 2016-10-31 Composition pharmaceutique contenant, en tant que principe actif, un dérivé ou un sel pharmaceutiquement acceptable de 7-azaindolin-2-one

Country Status (18)

Country Link
US (1) US10544140B2 (fr)
EP (1) EP3363799A4 (fr)
JP (1) JP6661766B2 (fr)
KR (1) KR102109869B1 (fr)
CN (1) CN108368108B (fr)
AU (1) AU2016353573B2 (fr)
BR (1) BR112018009482A2 (fr)
CA (1) CA3004595A1 (fr)
CL (1) CL2018001236A1 (fr)
CO (1) CO2018005367A2 (fr)
EA (1) EA201891136A1 (fr)
IL (1) IL259083A (fr)
MA (1) MA42361A1 (fr)
MX (1) MX2018005894A (fr)
NZ (1) NZ742228A (fr)
PH (1) PH12018500946A1 (fr)
WO (1) WO2017082569A1 (fr)
ZA (1) ZA201803722B (fr)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9721437D0 (en) * 1997-10-10 1997-12-10 Glaxo Group Ltd Heteroaromatic compounds and their use in medicine
JP2002522452A (ja) * 1998-08-04 2002-07-23 スージェン・インコーポレーテッド 蛋白質キナーゼの調節剤３−メチリデニル−２−インドリノン
EP1244672B1 (fr) * 1999-12-21 2005-07-20 Sugen, Inc. 7-aza-indoline-2-ones substitues en 4 et leur utilisation comme inhibiteurs de proteine kinase
CN102066362B (zh) * 2008-05-23 2014-07-30 上海医药工业研究院 二氢吲哚酮衍生物
US9040555B2 (en) * 2012-01-26 2015-05-26 Angion Biomedica Corp. Antifibrotic compounds and uses thereof
US10485800B2 (en) 2012-11-30 2019-11-26 The University Of Rochester Mixed lineage kinase inhibitors for HIV/AIDS therapies
US9187454B2 (en) * 2013-03-13 2015-11-17 Boston Biomedical, Inc. Inhibitors of kinases and cancer stem cells, and methods of preparation and use thereof
BR112015022431A2 (pt) * 2013-03-13 2017-05-09 Boston Biomedical Inc derivados de 3-(aril ou heteroaril) metilenoindolin-2-ona como inibidores de quinases da via de sinalização de células-tronco cancerosas para o tratamento de câncer
CN104876928B (zh) * 2015-05-07 2016-09-14 浙江司太立制药股份有限公司 7-氮杂吲哚啉-2-酮类化合物及其制备方法

Also Published As

Publication number Publication date
KR20170056430A (ko) 2017-05-23
CN108368108A (zh) 2018-08-03
KR102109869B1 (ko) 2020-05-13
EP3363799A4 (fr) 2018-12-05
ZA201803722B (en) 2019-03-27
CN108368108B (zh) 2021-09-21
AU2016353573B2 (en) 2019-11-21
WO2017082569A1 (fr) 2017-05-18
CA3004595A1 (fr) 2017-05-18
PH12018500946A1 (en) 2018-11-12
AU2016353573A1 (en) 2018-05-24
JP6661766B2 (ja) 2020-03-11
IL259083A (en) 2018-06-28
CL2018001236A1 (es) 2018-08-24
US10544140B2 (en) 2020-01-28
US20180370964A1 (en) 2018-12-27
JP2018533600A (ja) 2018-11-15
CO2018005367A2 (es) 2018-06-12
MX2018005894A (es) 2018-08-15
BR112018009482A2 (pt) 2018-11-06
EA201891136A1 (ru) 2018-10-31
EP3363799A1 (fr) 2018-08-22
NZ742228A (en) 2019-09-27

Similar Documents

Publication Publication Date Title
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
MX2021006035A (es) Formulaciones cannabinoides estables.
EA201691242A1 (ru) Фармацевтические композиции, содержащие azd9291
EA201790492A1 (ru) СОЕДИНЕНИЯ, КОТОРЫЕ ИНГИБИРУЮТ БЕЛОК Mcl-1
EA201591003A1 (ru) Производные бороновой кислоты и их терапевтическое применение
MA35753B1 (fr) Aryl-dihydropyridinones et pipéridinones en tant qu'inhibiteurs de mgat2
EA201791259A1 (ru) Производные пиперидина в качестве ингибиторов hdac1/2
EA202190960A1 (ru) Конденсированные пирролины, которые действуют как ингибиторы убиквитин-специфической протеазы 30 (usp30)
MA39443A1 (fr) Nouvelle formulation de méloxicam
MA43876B1 (fr) Compositions pharmaceutiques et leur utilisations contre les maladies de surcharge lysosomale
EA201992542A1 (ru) Фармацевтическая композиция для местного применения, содержащая, по меньшей мере, амитриптилин, для лечения периферической нейропатической боли
CL2018003431A1 (es) Tratamiento de la enfermedad de parkinson.
EA201790949A1 (ru) Замещенные 2,4-диаминохинолины в качестве новых противораковых средств
EA202190588A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина
SA521422152B1 (ar) Vanin مركبات عطرية غير متجانسة كمثبطات
EA201890534A1 (ru) Новые аннелированные феноксиацетамиды
EA201890906A1 (ru) ПРОИЗВОДНЫЕ ХИНОКСАЛИНА И ПИРИДОПИРАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ
MX2019006773A (es) Dexmedetomidina o medetomidina para uso en el tratamiento de la ansiedad por separacion en perros.
EA201591649A1 (ru) Составы с органическими соединениями
JOP20180071B1 (ar) استخدام مشتقات أمينو ألكيل بنزوثيازبين
EA202090164A1 (ru) Изотретиноиновые перорально-слизистые композиции и способы их применения
MA46039B1 (fr) Dérivé de triazolopyrazinone utile en tant qu'inhibiteur de pde1 humain
EA202191477A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина
MX2023006235A (es) Composiciones para administracion de farmacos y metodos de uso de las mismas.
EA201990550A1 (ru) Офтальмологический препарат, включающий азоловое соединение